CHEMBIO DIAGNOSTICS, INC. Form 8-K November 16, 2005

## SECURITIES AND EXCHANGE COMMISSION

### Washington, D.C. 20549

### FORM 8-K

#### **CURRENT REPORT**

## PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 15, 2005 CHEMBIO DIAGNOSTIC, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-30379	88-0425691
(State or other	(Commission	(IRS
jurisdiction	File Number)	Employer
of		Identification
Incorporation)		Number)
	3661	
	Horseblock	
	Road	
	Medford, NY	
	11763	
	(Address of	
	principal	
	executive	
	offices)	
	631-924-1135	
	(Registrant's	
	Telephone	
	Number)	

#### N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

# Edgar Filing: CHEMBIO DIAGNOSTICS, INC. - Form 8-K

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# ITEM 3.02. Unregistered Sales of Equity Securities.

On November 15, 2005, the Company issued 317,859 shares of restricted common stock as payment of dividends on the Company's series A preferred stock. No cash was exchanged in this issuance. The Company relied on Section 4(2) of the Securities Act of 1933 as the basis for its exemption from registration of this issuance. The investors in the issuance were accredited investors of the Company.

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 16, 2005 Chembio Diagnostics, Inc.

By: <u>/s/ Lawrence A. Siebert</u> Lawrence A. Siebert Chief Executive Officer